Brokers Issue Forecasts for Aurinia Pharmaceuticals Inc.’s Q4 2024 Earnings (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) – Investment analysts at Leerink Partnrs increased their Q4 2024 earnings per share estimates for Aurinia Pharmaceuticals in a report released on Thursday, May 2nd. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will earn $0.12 per share for the quarter, up from their previous estimate of $0.09. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is ($0.06) per share. Leerink Partnrs also issued estimates for Aurinia Pharmaceuticals’ FY2025 earnings at $0.23 EPS.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, February 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). Aurinia Pharmaceuticals had a negative net margin of 32.69% and a negative return on equity of 15.06%. The business had revenue of $45.10 million for the quarter, compared to the consensus estimate of $45.00 million. During the same quarter in the previous year, the company earned ($0.18) EPS. The firm’s revenue for the quarter was up 58.8% on a year-over-year basis.

AUPH has been the subject of several other reports. Royal Bank of Canada decreased their target price on shares of Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, March 1st. Cantor Fitzgerald cut their price target on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. StockNews.com raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Jefferies Financial Group dropped their price objective on Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating on the stock in a research note on Friday, February 16th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH opened at $5.16 on Monday. The company has a quick ratio of 5.05, a current ratio of 5.60 and a debt-to-equity ratio of 0.19. Aurinia Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $12.43. The company has a fifty day moving average of $5.18 and a 200-day moving average of $7.08. The firm has a market capitalization of $737.98 million, a P/E ratio of -12.00 and a beta of 1.36.

Institutional Trading of Aurinia Pharmaceuticals

Several large investors have recently bought and sold shares of AUPH. China Universal Asset Management Co. Ltd. grew its stake in Aurinia Pharmaceuticals by 95.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,673 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,798 shares during the period. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $30,000. Tidemark LLC bought a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $39,000. DekaBank Deutsche Girozentrale purchased a new position in Aurinia Pharmaceuticals during the 3rd quarter valued at about $65,000. Finally, Eagle Asset Management Inc. bought a new stake in Aurinia Pharmaceuticals during the fourth quarter worth about $92,000. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.